Navigation Links
Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
Date:4/7/2013

ults in significantly altered immune cell populations in the tumor microenvironment compared to the clinically validated IL-2 protein therapy, aldesleukin.  Specifically, NKTR-214 maintains high affinity for the IL-2 receptor subunit beta, which activates tumor-killing T cells within the tumor microenvironment.  At the same time, NKTR-214 exhibits up to 100-fold reduced affinity to the IL-2 receptor subunit alpha-beta, which activates immuno-suppressive regulatory T-cells.  In a well-validated animal model of melanoma, NKTR-214 demonstrated significantly improved dosing, at once every 9 days as compared to twice a day dosing with aldesleukin.

The data was presented today at the AACR Annual Meeting 2013 in Poster Session, Immunology 2, (Abstract #482): Charych, et al., "Tipping the balance in the tumor microenvironment: An engineered cytokine (NKTR-214) with altered IL-2 receptor binding selectivity and improved efficacy in a mouse melanoma model."About Nektar 
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in pain, oncology and other therapeutic areas.  In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 clinical development as a once- daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid. In the proprietary pipeline, NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinica
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
2. Advance Recruitment Delighted With Positive Outlook for Medical Device Sales Industry
3. Life Extension Foundation® study finds Cognitex® with NeuroProtection Complex may provide a positive impact on cognitive performance
4. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
5. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
6. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
8. Scioderm Announces Positive Phase II Data of Topical SD-101 on Wound Closure and Reduction of Lesions and Blisters in Children with Epidermolysis Bullosa (EB)
9. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
10. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
11. Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Pa. , May 29, 2015 ... focus of the Association for the Advancement of ... With support from AAWC,s corporate partners, ... Educational Portal on the AAWC website at ... a wound care pathway with links to various ...
(Date:5/28/2015)... HOUSTON , May 28, 2015 /PRNewswire/ - ESSA ... financial results for the second quarter and three and six ... expressed in Canadian dollars and in accordance with International Financial ... ESSA recorded a net loss of $5.9 million ($0.35 ... 2015 (Q2-2015), compared to a net loss of $0.4 million ...
(Date:5/28/2015)... 28, 2015  Maetrics ( http://maetrics.com ), a leading ... wrapped up a successful conference, "The cost of non-compliance -- ... today in Zurich . ... its Switzerland -based team, experts provided ... Technology field to an exclusive local audience. The event ...
Breaking Medicine Technology:The Association for the Advancement of Wound Care Educates the Public 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5Maetrics Hosts Innovative Medical Cluster Event in Switzerland 2
... Associates, of New Jersey awarded General Program Prize Paper at ... ... 18 Researchers at,Reproductive Medicine Associates of New Jersey (RMA) ... Reproductive Medicine (ASRM),for developing a novel technology making it possible ...
... Corporation,announced today that enrollment has completed in a ... to enhance memory. The,IMPACT ("Improvement in Memory with ... than five hundred adults aged 65+,seeking to improve ... Principal Investigators for the IMPACT trial are Elizabeth ...
Cached Medicine Technology:Researchers Develop New Procedure to Screen All 46 Human Chromosomes to Identify Abnormalities in Embryos 2Researchers Develop New Procedure to Screen All 46 Human Chromosomes to Identify Abnormalities in Embryos 3Study Demonstrates Mindful Approach to Aging 2Study Demonstrates Mindful Approach to Aging 3
(Date:5/29/2015)... 29, 2015 What does community do? ... Foundation, community comes together to plant gardens, to teach ... and awareness of critical issues. Community invites everyone to ... beyond. , "What Community Does" was commissioned by The ... Colorado, and released during the foundation’s Annual Celebration in ...
(Date:5/29/2015)... Washington, PA (PRWEB) May 29, 2015 ... ” quiz-based learning in 14 medical specialties, now offers ... includes a wide spectrum of rheumatology disorders ranging from ... Alfred Saint Jacques, editorial director of MDLinx, and Caroline ... excited about the impact it will have on the ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 John A. ... to Cincinnati , The Department of Veterans Affairs (VA) ... Gennaro as the new director of the Cincinnati VA ... care to more than 43,000 unique Veterans annually and ... over 2,000 staff, CVAMC is a two-division campus located ...
(Date:5/29/2015)... CO (PRWEB) May 29, 2015 ... new addiction, substance abuse, and co-occurring mental health ... and ribbon cutting for the general public on ... 2nd. , The Recovery Village at Palmer Lake ... intensive outpatient programming, utilizing traditional and evidence-based therapies, ...
(Date:5/29/2015)... Dot Hill can mark one more item off her bucket list: ... retirement community is the oldest woman to have flown at ... great fun!”, she exclaimed. “I’ve always wanted to jump from ... thought this would be ok.” , “We put on nylon coveralls, ... described. “I don’t remember it being noisy, but the wind ...
Breaking Medicine News(10 mins):Health News:What Community Does: A New Video from The Denver Foundation 2Health News:MDLinx Launches Smartest Rheumatologist 2Health News:VA Healthcare System of Ohio Network Announces New Medical Center Director 2Health News:Advanced Recovery Systems Announces the Opening of The Recovery Village at Palmer Lake 2Health News:Indoor Skydiving Brings Thrills to Seniors 2
... LOUISVILLE, Ky., Dec. 5 Ventas, Inc. ... that the Executive,Compensation Committee of its Board ... to certain executive officers to encourage their,long-term ... granted to,Raymond J. Lewis, the Company,s Chief ...
... -- Apart from a more complicated medical case, ... time with their patients" Researchers at UC Davis ... that affect the length of a patients medical ... the doctors visit. , In a new ...
... gene involved in communication among brain cells has a direct ... study by scientists supported by the National Institute on Alcohol ... Health (NIH), and the U.S. Army. , Scientists do not ... effect on alcohol consumption, exists in humans. , Known ...
... Ltd., (Amex: CPD ) announced today that ... final approval for the Company,s,Abbreviated New Drug Application ... and 10 mg (Amlodipine)., Amlodipine is indicated ... of chronic stable angina, and for the treatment ...
... Software Healthcare, Inc.,announced today that more than 500 ... Management system during the 2007 fiscal year,with the ... EHR by,Sage Electronic Health Records system., "Electronic ... our,customer base as well as new customers. These ...
... with those already carrying the virus , WEDNESDAY, Dec. 5 ... virus that causes AIDS) choose to have unprotected sex only ... from six clinics in San Francisco, New York City, Los ... study included 27 men with acute HIV infection. This refers ...
Cached Medicine News:Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 2Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 3Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 4Health News:New UC Davis study finds physician style and HMO affiliation impact lengths of patient visit 2Health News:Scientists identify gene that influences alcohol consumption 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R) 2Health News:Sage Software Healthcare, Inc. Announces Intergy by Sage and Intergy EHR by Sage installations for 2007 2Health News:Newly HIV-Infected Gay Men Select Other Infected Partners 2
The Onyx® 9500 worlds first self-contained digital fingertip pulse oximeter incorporates the electronics and the sensor into one unit....
The SportStat Pulse Oximeter shines red and infrared light through a finger and detects the fluctuating signals caused by blood flow. Pulse rate is determined from the signals received by a light det...
Ergonomically designed, the Invacare Printing Pulse Oximeter provides fast, reliable spot-check information and documentation of SpO2 and pulse rate. It is ideal for all patients from neonate to adul...
The FetalSAT™ System with DualSens Sensor displays continuous, real-time fetal pulse oximetry (FSpO2) and fetal pulse rate (FPR) values in one compact monitor....
Medicine Products: